Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$21.31K$21.31Kno prior Q3 2017 on file Net Income-$5.95M-$5.95MN/M vs Q3 2017 EPS Diluted-$0.02-$0.02N/M vs Q3 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$830,378N/M Free Cash Flowderived-$830,378— Margins · derivedGross margin79.8%
Operating margin-4858.8%
Net margin-27917.9%
ended Sep 30, 2018 · filed Nov 13, 2018 · 44 d after period end